Your AI-Trained Oncology Knowledge Connection!
In an interview with CancerNetwork® during National Colorectal Cancer Awareness Month, Rachel Pearlman, MS, LGC, highlights recent updates in genetic testing in colorectal cancer and where the field needs to head to provide individuals with better options.
A new drug application for futibatinib has been accepted for priority review in patients with previously treated locally advanced or metastatic cholangiocarcinoma with FGFR2 gene rearrangements.
Patients with cancer are at a higher risk for adverse financial effects compared with those who have not been diagnosed.
Candice Roth, MSN, RN, CENP, spoke about how the electronic treatment pathways have evolved over time.
Ira Winer, MD, PhD, FACOG, spoke about which presentations during The Society of Gynecologic Oncology 2022 Annual Meeting he most enjoyed.
While quality of life did not improve with esophageal-sparing intensity-modulated radiotherapy, patients with stage III/IV non–small cell lung cancer did experience a reduction in symptomatic esophagitis.
A biologics license application for mirvetuximab soravtansine, which demonstrated a clinically meaningful objective response rate, was submitted to the FDA for folate receptor α-high platinum-resistant ovarian cancer that has previously been treated with 1 to 3 lines of systemic treatments.
A real-world study using a voluntary questionnaire found an association between increased pain severity and decreased health-related quality of life for patients with multiple myeloma.
Laurence Albigès, MD, PhD, discusses how immunotherapy combinations have affected the treatment landscape for previously untreated advanced or metastatic renal cell carcinoma.
Brian Slomovitz, MD, Reviews Adjuvant Pembrolizumab and Chemo +/– Radiotherapy in Endometrial Cancer
At SGO 2022, CancerNetwork® spoke with Jyoti Mayadev, MD, about a clinical trial involving immune priming with the PD-L1 inhibitor atezolizumab for patients with locally advanced cervical cancer.
Although clinical trial enrollment declined among patients with lung cancer from 2019 to 2020 during the COVID-19 pandemic, mitigation strategies helped to improve enrollment.
The FDA supported submission of application for approval of zandelisib in follicular lymphoma and other indolent non-Hodgkin lymphomas based on the phase 3 COASTAL trial.
Tanios Bekaii-Saab, MD; Kristen Ciombor, MD, MSCI; and John Strickler, MD, detail key developments and needs in the gastrointestinal cancers landscape.
Experts provide their recommendations for navigating a large and continuously growing treatment landscape, selecting between regimens, and monitoring patients with transplant-ineligible multiple myeloma.
Laurence Albigès, MD, PhD, spotlighted 2-year follow-up data from the phase 3 CheckMate 9ER trial, which looked at nivolumab and cabozantinib in patients with previously untreated advanced or metastatic renal cell carcinoma.
Various healthcare professionals join to discuss the management of a patient diagnosed with HER2-positive breast cancer and consider how to best approach newer treatment strategies through her continuum of care.
Laurence Albigès, MD, PhD, speaks to how patients with treatment-naïve advanced or metastatic renal cell carcinoma can benefit from treatment with nivolumab and ipilimumab.
Patients with prostate cancer who received surgery had the highest rate of treatment-related regret followed by radiotherapy and active surveillance.
Patients with locally advanced cervical cancer did not see further benefit from the addition of concurrent durvalumab to chemoradiotherapy.
Prospective data found higher rates of occult signet ring cell gastric cancer among individuals with no family history of gastric cancer but who carried CDH1 P/LP variants.
Laurence Albigès, MD, PhD, shares updated key findings from the phase 3 CheckMate 214 trial.
Gennady Bratslavsky, MD, spoke about the evolving field of surgery for renal cell carcinoma at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.
Patients with clinically lymph node–positive breast cancer who achieved cN0 disease following treatment neoadjuvant chemotherapy with 3 or more negative sentinel lymphoma nodes identified by sentinel lymphoma node biopsy alone had a decrease in nodal recurrence.
A biologics license application for sintilimab plus chemotherapy in first-line nonsquamous non–small cell lung cancer was not approved by the FDA and a complete response letter was issued to the drug developer.
Gennady Bratslavsky, MD, spoke about the evolution for treatments in renal cell carcinoma and how surgery may play a role.
Based on data from the phase 3 VISION trial, 177Lu-PSMA-617 may now be used to treat patients who were previously treated with androgen receptor pathway inhibitors plus taxane-based chemotherapy for metastatic prostate specific membrane antigen–positive castration-resistant prostate cancer.
The 6.5-year updated analysis of the phase 3 CheckMate 067 trial highlighted notable overall survival benefit with nivolumab alone or in combination with ipilimumab for patients with advanced melanoma.
Findings from a meta-analysis indicated that pathologic complete response is a notable predictor of outcomes in HER2-positive breast cancer.
Axel Merseburger, MD, PhD, spoke about implementing the treatment combination of enzalutamide plus docetaxel/prednisone for progressive castration-resistant prostate cancer from the PRESIDE trial into the real-world.
